Abstract | CONTEXT: OBJECTIVE: DESIGN AND SETTING: We conducted a randomized, controlled, double-blind study at a tertiary referral center. PATIENTS AND INTERVENTIONS: Forty premenopausal women with PCOS were allocated to receive treatment with either pioglitazone (30 mg/d) or a placebo for a period of 3 months. MAIN OUTCOME MEASURES: RESULTS: CONCLUSIONS: Our results suggest that RBP4 may contribute to endocrine changes and to the phenotypic manifestation of patients with PCOS because higher RBP4 concentrations are associated with higher androgen levels and higher clinical hirsutism scores independently of pioglitazone treatment. The molecular involvement of RBP4 in human steroid metabolism requires further clarification.
|
Authors | Elmar Aigner, Nora Bachofner, Kerstin Klein, Christian De Geyter, Florian Hohla, Wolfgang Patsch, Christian Datz |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 94
Issue 4
Pg. 1229-35
(Apr 2009)
ISSN: 1945-7197 [Electronic] United States |
PMID | 19158194
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adipokines
- Blood Glucose
- Hypoglycemic Agents
- Insulin
- Placebos
- RBP4 protein, human
- Retinol-Binding Proteins, Plasma
- Thiazolidinediones
- Testosterone
- Pioglitazone
|
Topics |
- Adipokines
(blood)
- Adult
- Area Under Curve
- Blood Glucose
(metabolism)
- Double-Blind Method
- Female
- Hirsutism
(blood, epidemiology)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Insulin
(blood)
- Pioglitazone
- Placebos
- Polycystic Ovary Syndrome
(blood, drug therapy)
- Premenopause
- Retinol-Binding Proteins, Plasma
(drug effects, metabolism)
- Testosterone
(blood)
- Thiazolidinediones
(therapeutic use)
|